ALAB Form 4: Director Jack Lazar disposes of 22,500 shares via 10b5-1
Rhea-AI Filing Summary
Astera Labs director Jack R. Lazar reported automatic sales of common stock under a Rule 10b5-1 trading plan adopted May 28, 2025. On 08/27/2025 the Form 4 shows five sale transactions totaling 22,500 shares sold in multiple trades at weighted-average prices ranging from about $176.73 to $183.09. The filing lists the reporter's beneficial ownership following the reported sales as 97,351 shares held directly. The Form 4 was signed by an attorney-in-fact on 08/28/2025 and includes footnotes disclosing price ranges for each grouped sale.
Positive
- Sales executed under a documented Rule 10b5-1 plan, which supports procedural compliance and an affirmative-defense record
- Detailed disclosure of weighted-average prices and price ranges with an undertaking to provide per-trade price information on request
- Reporting person remains a director and retains 97,351 shares after the reported transactions
Negative
- Director sold a total of 22,500 shares on 08/27/2025, reducing direct holdings
- Multiple sales at varying prices may be interpreted by some market participants as a notable insider disposition (no further context provided)
Insights
TL;DR: Insiders used a pre-established 10b5-1 plan to sell a block of shares, preserving procedural compliance and transparency.
The Form 4 documents that Director Jack R. Lazar executed multiple automated sales under a Rule 10b5-1 plan adopted on May 28, 2025, which helps establish an affirmative defense against insider trading claims. The filing discloses weighted-average prices and price ranges for the grouped transactions and shows continuing direct ownership of 97,351 shares after the sales. From a governance standpoint, the filing is complete in that it identifies the 10b5-1 plan, reports granular sale volumes, and provides undertakings to supply transaction-level price details on request.
TL;DR: The sales are material in size but appear routine under a trading plan; no new company operational information is disclosed.
The transaction data show five sales on 08/27/2025 totaling 22,500 shares at weighted-average prices between approximately $176.73 and $183.09, leaving the reporting person with 97,351 shares. The filing contains explanatory footnotes on price ranges and a commitment to provide detailed execution information if requested. There is no additional financial or operational data in the Form 4 that would alter company valuation or outlook; the record simply updates insider holdings and executed sales method (10b5-1).
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,553 | $176.7342 | $274K |
| Sale | Common Stock | 8,718 | $177.7289 | $1.55M |
| Sale | Common Stock | 8,706 | $178.8253 | $1.56M |
| Sale | Common Stock | 3,450 | $179.7885 | $620K |
| Sale | Common Stock | 73 | $183.0903 | $13K |
Footnotes (1)
- The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $176.2100 to $177.0500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $177.3100 to $178.2800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $178.3200 to $179.3050, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $179.3800 to $180.1100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $182.3100 to $183.2000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
